CFO
TGTX icon

Callan Family Office’s TG Therapeutics TGTX Stock Holding History

Callan Family Office’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Buy
+4,878
New +$200K 0.01% 1047

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Callan Family Office's TGTX Position: Q2 2026 in Review

Callan Family Office opened a new position in TG Therapeutics (TGTX) in Q2 2026: 4,878 shares worth $268K. The stake represents 0.01% of the portfolio and ranks #1047 among its holdings.

427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Callan Family Office held 4,878 shares of TG Therapeutics worth $268K as of Q2 2026.
  • TG Therapeutics was a new Callan Family Office position in Q2 2026.
  • TG Therapeutics made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #1047 holding.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.